Morgan Stanley Lowers Fractyl Health (NASDAQ:GUTS) Price Target to $10.00

Fractyl Health (NASDAQ:GUTS) had its price target reduced by stock analysts at Morgan Stanley from $18.00 to $10.00 in a research note issued on Monday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock.

Fractyl Health Stock Performance

NASDAQ GUTS opened at $1.53 on Monday. The business’s 50-day moving average price is $2.05 and its 200 day moving average price is $2.49. The company has a quick ratio of 5.57, a current ratio of 5.58 and a debt-to-equity ratio of 0.60. The firm has a market cap of $73.59 million and a P/E ratio of -0.13. Fractyl Health has a 52-week low of $1.52 and a 52-week high of $13.99.

Fractyl Health (NASDAQ:GUTS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. On average, equities research analysts expect that Fractyl Health will post -1.66 earnings per share for the current year.

Insider Transactions at Fractyl Health

In related news, insider Jay David Caplan sold 64,197 shares of the company’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $158,566.59. Following the transaction, the insider now owns 153,544 shares of the company’s stock, valued at $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Harith Rajagopalan sold 90,972 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $1.82, for a total value of $165,569.04. Following the completion of the transaction, the chief executive officer now owns 491,329 shares of the company’s stock, valued at $894,218.78. The trade was a 15.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 274,032 shares of company stock worth $602,979 over the last ninety days.

Institutional Trading of Fractyl Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets increased its holdings in Fractyl Health by 54.1% in the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after buying an additional 7,397 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Fractyl Health by 27.3% in the 4th quarter. Bank of New York Mellon Corp now owns 41,448 shares of the company’s stock worth $85,000 after acquiring an additional 8,886 shares during the period. Jane Street Group LLC purchased a new position in Fractyl Health in the 3rd quarter valued at approximately $25,000. Rhumbline Advisers raised its holdings in Fractyl Health by 73.1% during the fourth quarter. Rhumbline Advisers now owns 25,626 shares of the company’s stock worth $53,000 after purchasing an additional 10,826 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Fractyl Health by 335.4% during the third quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company’s stock worth $37,000 after purchasing an additional 11,406 shares in the last quarter.

Fractyl Health Company Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.